VENUSREM quarterly results and annual financials: sales, operating profit, OPM, net profit, EPS, balance sheet, cash flow and ratios like ROCE, with YoY and QoQ growth.
Venus Remedies Ltd reported sales of ₹219 Cr, operating profit of ₹42 Cr (OPM 19%) and net profit of ₹26 Cr for the quarter ended Sep 2026. Figures in ₹ crore, consolidated where available.
VENUSREM quarterly results (₹ Cr)
Metric
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Sales
177
195
137
193
180
259
179
219
Expenses
158
166
122
162
143
196
145
176
Operating Profit
18
29
15
31
38
63
34
42
OPM
10%
15%
11%
16%
21%
24%
19%
19%
Other Income
12
7
3
2
3
5
3
1
Interest
0
0
0
0
0
0
0
0
Depreciation
5
5
6
6
7
7
7
10
Profit before tax
25
31
13
26
33
62
30
33
Tax
21%
32%
24%
24%
24%
23%
24%
23%
Net Profit
20
21
10
20
26
48
23
26
EPS in Rs
14.66
15.71
7.18
15.06
19.14
35.54
17.18
19.19
VENUSREM profit & loss, annual (₹ Cr)
Metric
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
TTM
Sales
597
552
596
645
766
837
Expenses
535
492
537
577
619
660
Operating Profit
62
60
60
69
147
178
OPM
10%
11%
10%
11%
19%
21%
Other Income
8
10
12
26
13
11
Interest
0
0
0
0
0
0
Depreciation
34
32
26
23
26
30
Profit before tax
36
38
45
72
134
159
Tax
-12%
30%
36%
37%
23%
-
Net Profit
41
27
28
45
103
122
EPS in Rs
30.46
19.88
21.31
33.9
76.9
91.05
Dividend Payout
0%
0%
0%
0%
13%
-
VENUSREM balance sheet (₹ Cr)
Metric
Mar 2024
Mar 2025
Sep 2025
Mar 2026
Sep 2026
Equity Capital
13
13
13
13
13
Reserves
474
548
581
650
691
Borrowings
41
2
14
12
12
Other Liabilities
98
153
159
178
123
Total Liabilities
627
716
768
854
840
Fixed Assets
219
229
237
232
217
CWIP
21
26
34
51
75
Investments
19
84
193
238
240
Other Assets
368
376
303
333
307
Total Assets
627
716
768
854
840
VENUSREM cash flows (₹ Cr)
Metric
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Cash from Operating Activity
41
37
37
86
156
Cash from Investing Activity
-17
-58
-8
-77
-185
Cash from Financing Activity
-9
-1
-1
-1
-3
Net Cash Flow
14
-22
28
9
-32
Free Cash Flow
41
29
24
69
118
CFO/OP
66%
61%
89%
160%
129%
CFO/EBITDAShare of operating profit converting into cash: CFO (before tax) / Operating Profit